Individuals Stopping Anti-Obesity Medications Regain Pounds at a Quadrupled Rate Compared to Dieters

Fresh analysis suggests that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on lost weight far faster than those who end conventional lifestyle plans.

Published data in a prominent medical journal points out that while overweight people frequently drop about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.

"Users using these treatments need to be informed of the danger of fast weight regain when the treatment concludes," warns expert Dr. Susan Jebb.

This pace of recovery suggests a return to starting weight in about 18 months.

Analyzing Treatments

The analysis, which examined dozens of trials involving thousands of patients, compared the effects of the injectable medications with older methods.

Scientists emphasize that people who lose weight through lifestyle changes alone generally see a less rapid weight regain—approximately 0.1 kg a month—after stopping.

Understanding the Quick Rebound

Experts believe the way of the jabs is key to understanding the amplified rebound.

GLP-1 drugs copy a body's own chemical called GLP-1, which controls feelings of fullness.

"Artificially providing the hormone concentrations far above than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this hormone supplement leads to appetite is uncontrolled, making overeating far more likely."

An Ongoing Issue?

Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.

A number of clinicians argue that, given the high risk of relapse, the therapy is often ongoing.

This opinion is supported by drug manufacturers, who state that the findings "underscore the chronic nature of obesity," similar to managing conditions like hypertension.

Patient Accounts

Individuals who have discontinued the jabs report a powerful resurgence of cravings.

"I experienced a switch that goes on and you become ravenous," said a patient.

This challenge is exacerbated if users have not developed sustainable dietary or behavioural modifications during treatment.

Growing Interest

Figures show that millions of adults in the UK have tried these injections in the past year, with desire remaining high.

• Use is higher among females compared to males.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion obtain the medications through private prescriptions rather than public health services.

In conclusion, researchers emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and lasting health benefits relies on ongoing lifestyle management.